Loading
Life sciences · Journal article
Journal of the American Chemical Society · September 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Sonodynamic therapy (SDT) offers deep-tissue penetration but is limited by the lack of reliable strategies to predict intersystem crossing efficiency in sonosensitizers. Here, we identify two ground-state electronic descriptors, namely, the orbital center-of-mass distance (DH–L) and the orbital overlap integral (VH–L), that quantitatively correlate with intersystem crossing rates governed by orbital transition characteristics. These descriptors avoid computationally intensive excited-state calculations while maintaining strong predictive power. Guided by this strategy, we developed a series of donor–acceptor sonosensitizers with enhanced reactive oxygen species (ROS) generation under ultrasound (US) irradiation, as validated by both theoretical analysis and experimental measurements. The optimized sonosensitizer was further formulated into DPBRMN NPs that incorporate a hypoxia-responsive, BRD4-targeted PROTAC prodrug. This integrated platform enables tumor-selective ROS production together with in situ protein degradation-mediated immune activation, leading to effective suppression of primary tumors and distant metastases. This work establishes a descriptor-guided framework for sonosensitizer design and provides a molecular strategy for integrating sonodynamic therapy with targeted protein degradation to enhance cancer immunotherapy.